Freeline
Stevenage
About Freeline
Freeline is a clinical biotechnology company that develops transformative adeno-associated virus-vector-mediated systemic gene therapies. They use a designed AAV vector and capsid along with novel promoters and transgenes to deliver a functional copy of a therapeutic gene into human liver cells to express a functional level of the missing or dysfunctional protein into the patient’s bloodstream. Their development programs including clinical trials focus on developing products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $302.1M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2022)
- Ticker: nasdaq:FRLN
- Website: freeline.life
- Phone: +44 (0)1438 906870
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/freeline-134683 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.